Announcement • Nov 12
Pacific Software, Inc. (OTCPK:PFSF) acquired 10763942 Canada Inc. and PurMinds Asset Portfolio from PurMinds NeuroPharma Inc. Pacific Software, Inc. (OTCPK:PFSF) agreed to acquire 10763942 Canada Inc. and PurMinds Asset Portfolio from PurMinds NeuroPharma Inc. on August 25, 2025. As part of the acquisition, the current management team of 107 Canada is expected to assume leadership roles in the company and elect a new Board of Directors of Pacific Software Inc. which may consider a name change to PurMinds Enterprises, if available.
Pacific Software, Inc. (OTCPK:PFSF) completed the acquisition of 10763942 Canada Inc. and PurMinds Asset Portfolio from PurMinds NeuroPharma Inc. on November 11, 2025. The common stock is now quoted on the OTC market platform. Following completion, the PurMinds management team has assumed leadership roles and is considering a corporate name change to PurMinds Enterprises pending approval by FINRA. Announcement • Jul 23
Robert Schiestl Joins Pacific Software Inc. as Chief Science Advisor Pacific Software Inc. announced the appointment of Professor Dr. Robert Schiestl Ph.D. as its Chief Science Advisor (CSA), effective immediately. Dr. Robert Schiestl is a distinguished scientist who received his Ph.D. from the University of Vienna, Austria with an extensive background in molecular toxicology, cancer prevention, and genomics. He was previously Assistant and Associate Professor in the Department of Cancer Research and later Toxicology at the Harvard School of Public Health. He is currently Professor Emeritus of Pathology, Environmental Health Sciences and Radiation Oncology at UCLA. He was a Director of the UCLA Center for Environmental Genomics, member of the UCLA Cancer Center and Occupational and Environmental Health Sciences. He was also a member of the Interdepartmental Program in molecular Toxicology (advisory committee) at UCLA. Dr. Schiestl has authored over 200 peer-reviewed publications and has been recognized with numerous awards for his research and contributions to science. Dr. Schiestl's work focuses on the mechanisms of genetic stability and the development of strategies to prevent genetic diseases and cancer. His research has provided significant insights into the field of oxidative stress and its impact on health, which aligns perfectly with the company’s mission to develop innovative skincare products and science-based dietary supplements. Dr. Schiestl’s Achievements and Contributions Include: Over 200 peer-reviewed publications in scientific journals, 9 press releases and 16 patents and 6 companies. Recipient of numerous awards including Outstanding Leadership Award in Healthcare 2022, Outstanding Visionary Award in Healthcare 2023, Outstanding Organization Award in Healthcare 2024, Outstanding Education Award 2023, The Outstanding MORE Leadership Award (Money and Real Estate) in 2023, Outstanding CXO Award 2024 as best CEO, the Outstanding Leadership Award in Internet 2024, The Best Speakership Award at The International Conference on Nursery, Patient Safety and Healthcare 2023. Pioneering research in genetic stability and cancer prevention and Health. Development of novel strategies to combat oxidative stress-related health issues. 
